ACTIV Partnership Records
Records received via the KEI-NIH Freedom of Information Act (FOIA) lawsuit regarding an April 17, 2020 FOIA request for records relating to the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, the private-public partnership announced by the National Institutes of Health (NIH) and the Foundation for the NIH (FNIH) to facilitate the development of COVID-19 treatments and vaccines. ACTIV is coordinated by the Foundation for the National Institutes of Health (FNIH), with the NIH and sibling agencies in the Department of Health and Human Services, including the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention (CDC), and the U.S. Food and Drug Administration (FDA), as well as other U.S. government agencies including the Department of Defense (DOD) and Department of Veterans Affairs (VA); Countermeasures Acceleration Group (formerly known as Operation Warp Speed), and the European Medicines Agency (EMA) and representatives from academia, philanthropic organizations, and numerous biopharmaceutical companies.
- https://archive.org/details/nih-activ-foia-54015
- KEI-NIH FOIA Lawsuit for NIH-FNIH Correspondence on COVID-19 Partnership – All Records
Francis Collins’ Correspondence with FNIH, Pharmaceutical Industry and Others
Records received via the KEI-NIH Freedom of Information Act (FOIA) lawsuit regarding an April 16, 2018 FOIA request for correspondence between then-NIH Director Francis Collins and representatives of the pharmaceutical industry and surrounding entities. This request sought Dr. Collins’ correspondences with persons representing the Foundation for the NIH (FNIH), Biotechnology Innovation Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA), Gilead, Roche, Genentech, Novartis, the Biden Cancer Initiative, certain individuals: Charles Sawyer, Carl Icahn, and Patrick Soon-Shiong, and members of the Accelerating Medicines Partnership (AMP) (a public-private partnership between the NIH, the U.S. Food and Drug Administration (FDA), 12 biopharmaceutical and life science companies and 13 non-profit organizations).”
- https://archive.org/details/francis-collins-nih-emails-industry-fnih-foia-march-2022-production
- https://archive.org/details/francis-collins-nih-emails-industry-fnih-foia-april-2022-production
- https://archive.org/details/francis-collins-nih-emails-industry-fnih-foia-feb-2022-production
- KEI-NIH FOIA Lawsuit for Francis Collins Correspondence – February 2022 Production- All Records
Mark Rohrbaugh Correspondence Regarding KEI
Records received via the KEI-NIH Freedom of Information Act (FOIA) lawsuit regarding a June 18, 2020 FOIA request for correspondence to/from Dr. Mark L. Rohrbaugh, Special Advisor for Technology Transfer at the National Institutes of Health (NIH) regarding Knowledge Ecology International (KEI).
- https://archive.org/details/mark-rohrbaugh-nih-foia-emails-re-kei
- KEI-NIH FOIA Lawsuit for Mark Rohrbaugh Correspondence regarding KEI – All Records
RADx Contracts
Records received via the KEI-NIH Freedom of Information Act (FOIA) lawsuit regarding a July 30, 2020 FOIA request to the National Institutes of Health (NIH) for contracts related to the NIH COVID-19 diagnostics initiative Rapid Acceleration of Diagnostics (RADx), which included seven contracts to Mesa Biotech, Quidel, Talis Biomedical, Ginkgo Bioworks, Helix OpCo, Fluidigm, and Mammoth Biosciences.
- KEI-NIH FOIA Lawsuit for COVID-19 Testing Initiative RADx Records
- February 2021 Production (All records)
Molnupiravir Records
Records received via the KEI-NIH Freedom of Information Act (FOIA) lawsuit regarding a August 24, 2020 FOIA request to the National Institutes of Health (NIH) for contracts and grant agreements related to COVID-19 treatment molnupiravir (EIDD-2801), which was developed by Emory University and Ridgeback Biotherapeutics.
- KEI-NIH FOIA Lawsuit for COVID-19 Treatment Molnupiravir Records – All Records